Navigation Links
Pharmacyclics Announces Date of Fiscal Year End 2011 Financial Results and Conference Call

SUNNYVALE, Calif., Sept. 8, 2011 /PRNewswire/ -- Pharmacyclics, Inc. (NASDAQ: PCYC), a biopharmaceutical company focused on developing and commercializing innovative small molecule drugs for the treatment of cancer and immune mediated diseases, today announced that it will report financial results for the fourth fiscal quarter and fiscal year ended June 30, 2011 after the NASDAQ Market closes on Monday, September 12, 2011.  The company will conduct a conference call and an audio webcast at 4:30 p.m. EDT on the same day. Fiscal Year End Quarter 2011 Conference Call and Webcast DetailsDate: September 12, 2011Time: 4:30 PM EDTListen via Internet: Toll-free: +1-877-407-8133International: +1-201-689-8040Replay Number (Toll Free): 877-660-6853  Replay Number (International): 201-612-7415Replay Passcodes (both required for playback):Account #: 286Conference ID #: 378850A webcast replay will be available on the Pharmacyclics website for 30 days.

About PharmacyclicsPharmacyclics® is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative small-molecule drugs for the treatment of cancer and immune mediated diseases. Our mission and goal is to build a viable biopharmaceutical company that designs, develops and commercializes novel therapies intended to improve quality of life, increase duration of life and resolve serious unmet medial healthcare needs; and to identify promising product candidates based on scientific development expertise, develop our products in a rapid, cost-efficient manner and pursue commercialization and/or development partners when and where appropriate.

Presently, Pharmacyclics has three product candidates in clinical development and several preclinical molecules in lead optimization. We are committed to high standards of ethics, scientific rigor, and operational efficiency as we move each of these programs to viable commercialization.

The Company is headquartered in Sunnyvale, California and is listed on NASDAQ under the symbol PCYC. To learn more about how Pharmacyclics advances science to improve human healthcare visit us at


SOURCE Pharmacyclics
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Pharmacyclics Reports Recent Developments From Clinical Studies of its Btk Inhibitor PCI-32765
2. Pharmacyclics Announces Oral Presentations and Clinical Update at Upcoming Medical Meetings
3. Pharmacyclics to Announce Third Quarter Fiscal 2011 Results and Host a Conference Call on May 4, 2011
4. Pharmacyclics to Announce Second Quarter Fiscal 2011 Results and Host a Conference Call on February 4, 2011
5. Pharmacyclics Reports Updated Clinical Results from its Phase IA Trial of its First in Human Btk-Inhibitor PCI-32765
6. Pharmacyclics Reports CLL Results from Preclinical and Clinical Studies of its Btk Inhibitor PCI-32765
7. Pharmacyclics Reports Financial Results for Fiscal 2010 and for Fourth Quarter 2010
8. Pharmacyclics Announces Date of Fiscal Year End 2010 Financial Results and Conference Call and Presentation at Stifel Nicolaus Healthcare Conference
9. Pharmacyclics to Present at Bank of America Merrill Lynch Healthcare Conference and MDB Bright Lights Conference
10. Pharmacyclics to Present at the RBC Capital Markets Healthcare Investor Conference
11. Pharmacyclics Reports Second Quarter Fiscal 2010 Financial Results
Post Your Comments:
(Date:11/30/2015)... Nuance Communications, Inc. (NASDAQ: NUAN ) and ... today jointly announced a new integrated set of clinical ... College of Radiology,s (ACR) Imaging 3.0™ tools to enable ... current and emerging value-based payment models . ... clinical decision support, radiology reporting and image sharing technology ...
(Date:11/30/2015)... HYDERABAD, India , Nov. 30, 2015 Varian Medical ... (MoU) to develop an educational partnership with Apollo Hospitals Group, the ... a program that will help train radiation technologists in the country. ... executive officer of Apollo Knowledge, and Ashok Kakkar , Varian,s ... . India , Varian intends ...
(Date:11/30/2015)... Belgium , Nov. 30, 2015   VolitionRx ... on developing blood-based diagnostic tests for a broad range of ... present at the LD Micro Conference, which will be held ... Attending from VolitionRx will be David Kratochvil ... , Vice President of Investor Relations. ® ...
Breaking Medicine Technology:
(Date:11/30/2015)... ... November 30, 2015 , ... Using a combination of two ... American children and adults, according to a new study by researchers at the School ... in Children and Adults: Using Combinations of Blood Glucose Tests ,” published in Frontiers ...
(Date:11/30/2015)... ... 30, 2015 , ... The recently published 32nd Annual Report ... reveals that in 2014, someone called a poison center about every 11 seconds. ... were human exposure cases. , The American Association of Poison Control Centers (AAPCC) ...
(Date:11/30/2015)... PA (PRWEB) , ... November 30, 2015 , ... ... Specialty Ingredients (ASI) as their exclusive channel partner for the Nutraceutical Specialties products ... markets in the US, effective immediately. , “We are pleased to announce ...
(Date:11/30/2015)... ... November 30, 2015 , ... ... announced at the Radiology Society of North America (RSNA) annual meeting, being held ... 60% growth from 2014. Throughout 2015, the company has completed installations for ...
(Date:11/30/2015)... ... November 30, 2015 , ... ... Kreithen”), one of the leading plastic surgery practices in Florida, is proud to ... to consult for surgical innovations giant Ethicon Inc., a Johnson & Johnson Company. ...
Breaking Medicine News(10 mins):